@article{oai:mdu.repo.nii.ac.jp:00002279,
 author = {ARA, TOSHIAKI and MAEDA, YOSHIHIRO and FUJINAMI, YOSHIAKI and IMAMURA, YASUHIRO and HATTORI, TOSHIMI and WANG, PAO-LI},
 issue = {6},
 journal = {Biological and Pharmaceutical Bulletin},
 month = {Jun},
 note = {application/pdf, In the present study, we investigated the anti-inflammatory effects of a Kampo medicine Shosaikoto (TJ-9) using in vitro periodontal disease model, in which human gingival fibroblasts (HGFs) treated with lipopolysaccharide (LPS) from Porphyromonas gingivalis (PgLPS) produce IL-6, IL-8 and prostaglandin E2 (PGE2). Treatment with PgLPS (10 ng/ml), TJ-9 (up to 1 mg/ml) and their combinations for 24 h did not affect the viability of HGFs. Moreover, TJ-9 did not alter LPS-induced IL-6 and IL-8 productions. However, TJ-9 significantly suppressed LPS-induced PGE2 production in a dose-dependent manner but TJ-9 alone did not affect basal PGE2 level. Western blotting demonstrated that TJ-9 decreased cyclooxygenase-2 (COX-2) expression in a dosedependent manner but not phospholipase A2. Moreover, TJ-9 selectively and dose-dependently inhibited COX-2 activity. These results suggest that TJ-9 decreased PGE2 production by inhibition of both COX-2 expression and activity and that TJ-9 may be useful to improve gingival inflammation in periodontal disease.},
 pages = {1141--1144},
 title = {Preventive effects of a Kampo Medicine, Shosaikoto, on inflammatory responses in LPS-Treated Human gingival fibroblasts},
 volume = {31},
 year = {2008}
}